Introduction
As one of the most aggressive and highly metastatic malignan≠ cies, lung cancer ranks first in cancer≠ related deaths worldwide (1, 2) . Metastasis is the leading cause of death among cancer patients (3, 4) . Tumor cell invasion and migration are critical aspects in cancer metastasis. However, the endogenous mech≠ anisms that suppress cancer invasion and metastasis remain to be elucidated.
The neuronal guidance cue SLIT comprises a family of secreted glycoproteins that were originally discovered to reg≠ ulate axonal guidance and neuronal migration by binding to roundabout (ROBO) receptors (5) (6) (7) (8) . Subsequent studies demonstrated that SLIT/ROBO signaling also plays important roles outside of the nervous system, such as in the modulation of chemokine activation and migration of cells from multiple lineages (9) (10) (11) (12) (13) . Recent studies suggest that the neuronal guid≠ ance molecule SLIT plays important roles in cancer (for recent reviews, see refs. 14-16). For instance, the SLIT2 gene is inacti≠ vated in multiple types of cancers, including lung cancer, often as a result of promoter hypermethylation or loss of heterozygos≠ ity (LOH) (17) (18) (19) (20) (21) . Nonetheless, the role of SLIT signaling in lung cancer and the underlying mechanisms are unclear.
To dissect the SLIT/ROBO signaling pathways, we searched for proteins interacting with the ROBO receptor and identified myosin 9b (Myo9b, also termed myosin IXb) as a ROBO≠ interacting protein.
Myo9b is an unconventional myosin family motor protein that moves along actin filaments (22, 23) . The vertebrate myosin IX family has 2 members: Myo9a and Myo9b. Myo9a is predominantly expressed in testis and brain (24) , whereas Myo9b has been reported in the immune cells (25, 26) . Different from other unconventional myosins, Myo9b contains a unique RhoGAP domain in its tail region in addi≠ tion to the head (motor) domain with ATP≠ and actin≠ binding sites and the neck domain with 4 isoleucine≠ glutamine (IQ) motifs (27) . Using this RhoGAP domain, Myo9b negatively regulates the small G protein RhoA, converting RhoA from the active GTP≠ bound form to the inactive GDP≠ bound form (25, 28, 29) . The small G protein RhoA plays an important role in modulating the actin cytoskeleton during cell migration (e.g., refs. 30, 31, and references within). However, the structural basis for Myo9b function in regulating RhoA was unclear. The mechanisms by which the extracellular signals from guidance cues are transmitted to RhoA or other GTPases, thereby organizing coordinated changes in the actin cytoskeleton to promote directional cell migration, remain to be understood.
Here, we report that Myo9b is a previously unknown ROBO≠ in≠ teracting protein that mediates the SLIT inhibitory effect on lung can≠ cer cell migration. We show that Myo9b specifically suppresses RhoA activation through its RhoGAP domain in lung cancer cells. Our x≠ ray crystallography data reveal that the Myo9b RhoGAP domain con≠ tains a unique patch that specifically recognizes RhoA. In lung can≠ Emerging evidence indicates that the neuronal guidance molecule SLIT plays a role in tumor suppression, as SLIT-encoding genes are inactivated in several types of cancer, including lung cancer; however, it is not clear how SLIT functions in lung cancer. Here, our data show that SLIT inhibits cancer cell migration by activating RhoA and that myosin 9b (Myo9b) is a ROBO-interacting protein that suppresses RhoA activity in lung cancer cells. Structural analyses revealed that the RhoGAP domain of Myo9b contains a unique patch that specifically recognizes RhoA. We also determined that the ROBO intracellular domain interacts with the Myo9b RhoGAP domain and inhibits its activity; therefore, SLIT-dependent activation of RhoA is mediated by ROBO inhibition of Myo9b. In a murine model, compared with control lung cancer cells, SLIT-expressing cells had a decreased capacity for tumor formation and lung metastasis. Evaluation of human lung cancer and adjacent nontumor tissues revealed that Myo9b is upregulated in the cancer tissue. Moreover, elevated Myo9b expression was associated with lung cancer progression and poor prognosis. Together, our data identify Myo9b as a key player in lung cancer and as a ROBOinteracting protein in what is, to the best of our knowledge, a newly defined SLIT/ROBO/Myo9b/RhoA signaling pathway that restricts lung cancer progression and metastasis. Additionally, our work suggests that targeting the SLIT/ROBO/Myo9b/RhoA pathway has potential as a diagnostic and therapeutic strategy for lung cancer.
Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression Ruirui Kong, 1 Fengshuang Yi, 2, 3 Pushuai Wen, 1 Jianghong Liu, 1 Xiaoping Chen, 4 Jinqi Ren, 2 Xiaofei Li, 5 Yulong Shang, 6 Yongzhan Nie, 6 Kaichun Wu, 6 Daiming Fan, 6 Li Zhu, 1 Wei Feng, 2 and Jane Y. Wu ine the expression of SLIT2 and its receptor ROBO1 in various cell lines, including H1299 cells, derived from human lung cancer tissue. In most lung cancer cell lines surveyed and in a significant fraction of primary lung cancer samples examined, SLIT2 expres≠ sion was low or nondetectable (Supplemental Figure 1A ; supple≠ mental material available online with this article; doi:10.1172/ JCI81673DS1). ROBO1 protein, however, was detected in these lung cancer cell lines by Western blotting analysis using a specific anti≠ ROBO1 Ab (Supplemental Figure 1B) .
To examine the effect of SLIT2 on lung cancer cell migra≠ tion, we set up a wound≠ healing assay using H1299 lung cancer cells. The cells were treated with the mock control or SLIT2≠ containing media after wound formation. SLIT2 treatment sig≠ nificantly inhibited the migration of H1299 cells (Figure 1, A  and B) . To test the role of ROBO1 in mediating SLIT2 activity in lung cancer cells, we used ROBO1N, the soluble extracel≠ lular domain of ROBO1 capable of blocking SLIT signaling (6, 13, 32) . Addition of ROBO1N to the wound≠ healing assay effec≠ cer cells, the intracellular domain (ICD) of ROBO directly interacts with the Myo9b RhoGAP domain and inhibits its activity. Thus, our data demonstrate that the negative regulation of Myo9b by SLIT/ ROBO signaling in lung cancer cells activates RhoA and inhibits cell migration. Supporting this model, our experiments showed that SLIT inhibits lung tumor invasion and metastasis in a xenograft mouse model. We found that Myo9b was highly expressed in human lung cancer tissues as compared with levels observed in the control sam≠ ples. Consistently, increased Myo9b expression was associated with lymph node metastasis, advanced tumor stage, and poor patient sur≠ vival. These results uncover what is, to our knowledge, a previously unknown SLIT/ROBO/Myo9b/RhoA signaling pathway that inhibits cell migration and suppresses lung cancer metastasis.
Results

SLIT2 inhibits cell migration by regulating
RhoA activity in lung can≠ cer cells. To investigate the involvement of SLIT/ROBO signaling in lung cancer pathogenesis, we first performed RT-PCR to exam≠ A wound-healing assay was performed using H1299 cells treated with control (Ctr), SLIT2 (SL), and ROBO1N (RN) media. At 0 and 13 hours after wound formation, phase-contrast images of migrating cells were obtained using an inverted microscope. Scale bar: 100 μm. Data represent 5 independent experiments. (B) Quantification of cell migration distance over a 13-hour period. Data represent the mean ± SEM of 3 independent experiments. ***P < 0.0001, Mann-Whitney U test. (C) H1299 cells were transfected with plasmids encoding either WT CDC42-Myc or Rac1-Myc and treated 48 hours after transfection with mock control or SLIT2 media for 5 or 15 minutes. Cell lysates were then prepared, a GST pull-down assay was performed using GST-PBD, and immunoblotting with anti-Myc Ab was done to measure active or total CDC42 or Rac1 levels in pull-down or total cell lysates, respectively. Active RhoA or total RhoA levels were measured by GST pull-down with GST-RBD and analyzed by immunoblotting with specific anti-RhoA Ab. SLIT protein levels in the culture media and actin (as an internal loading control) are also shown. (D and E) Cell migration in the H1299Ctr (Ctr) and H1299SLIT (SL) groups following transfection with a control vector or a Myc-tagged DN-RhoA plasmid as determined by wound-healing assay. Images were taken 0 and 12 hours after wound formation. Scale bar: 100 μm. n = 5. Data in E represent the mean ± SEM of 3 independent experiments. ***P < 0.0001, Mann-Whitney U test. jci.org ( Figure 1C , lanes 7-9), indicating that SLIT2 specifically modulates RhoA activity in lung cancer cells. We also used another method to examine SLIT2 activity in H1299 cells. Instead of adding SLIT2 to the culture media, we created 2 stable H1299 cell lines that over≠ expressed the human SLIT2 gene. We detected similar RhoA, but not CDC42 or Rac1, activation when SLIT was expressed in H1299 cells (Supplemental Figure 1E) . The observation that SLIT2 acti≠ vates RhoA, but not CDC42 or Rac1, in lung cancer cells suggests that the mechanism by which SLIT2 regulates small GTPase activ≠ ity in lung cancer cells is distinct from that in neurons.
To examine whether changes in RhoA activity were required for SLIT2 inhibition of lung cancer cell migration, we transfected H1299 control (H1299Ctr) and H1299 SLIT (H1299SLIT) cells with a dominant≠ negative form of RhoA (DN-RhoA) that was described previously (33) . Wound≠ healing experiments were per≠ formed to determine the effect of RhoA on cell migration. Expres≠ sion of the DN-RhoA mutant significantly reduced the inhibitory effect of SLIT2 on H1299 cell migration (Figure 1 , D and E), indi≠ cating that SLIT2 inhibits lung cancer cell migration in a RhoA≠ de≠ pendent manner. These data show that SLIT2 inhibits cell migra≠ tion by regulating RhoA activity in lung cancer cells.
Myo9b interacts with ROBO1 and mediates SLIT2≠ induced inhi≠ bition of cell migration and activation of RhoA. To dissect the SLIT/ ROBO signaling pathways, we have been searching for proteins that interact with the ICD of the ROBO1 protein (32, 33) . We performed yeast 2≠ hybrid screens, which identified one group of cDNA clones that encode the Myo9b protein, in addition to pre≠ viously reported genes including srGAPs (33) and USP33 (32) . RT-PCR and Western blotting experiments showed that Myo9b tively reversed the inhibitory effect of SLIT2 on lung cancer cell migration ( Figure 1, A and B) , indicating that SLIT2 inhibits H1299 cell migration in a ROBO1≠ dependent manner. We also tested SLIT2 activity in another human lung cancer cell line, A549, and found that SLIT2 suppressed the migration of A549 cells as well and that ROBO1N abolished the SLIT2 inhibitory effect (Supplemental Figure 1, C and D) .
To understand the molecular mechanism underlying SLIT2 function in lung cancer cells, we examined the signal transduction pathways involved. Our previous study indicated that SLIT reduces active CDC42 levels in neurons and that SLIT/ROBO GAP1 (srGAP1) is required for SLIT≠ induced suppression of CDC42 activity in neuronal migration (33) . We therefore asked whether the srGAP1/Cdc42 pathway, observed in neurons, mediated the SLIT inhibitory effect on lung cancer cell migration. We systematically examined the effect of SLIT2 on small GTPases including CDC42, Rac1, and RhoA. H1299 cells expressing Myc≠ tagged CDC42 or Rac1 were treated with control or SLIT2 for 5 minutes or 15 min≠ utes. Cell lysates were then incubated with GST-Pak≠ binding domain (GST-PBD), a protein domain specifically interacting with active (GTP≠ bound) CDC42 or Rac1 (30) . Extracts from H1299 cells treated with control or SLIT2 for 5 minutes or 15 minutes were incubated with a GSTñ rhotekin≠ binding domain (GST-RBD), which selectively binds to the active form of RhoA (34) . GTPases were detected in H1299 cell lysates by immunoblotting with corre≠ sponding Abs following the GST pull≠ down experiment. To our sur≠ prise, SLIT2 treatment did not affect active levels of either CDC42 or Rac1 ( Figure 1C, lanes 1-3 and lanes 4-6, respectively) . In con≠ trast, SLIT2 treatment remarkably increased active RhoA levels GST pull-down experiments and Western blotting were performed to measure active and total RhoA levels. jci.org ROBO1 is a transmembrane receptor containing 5 Ig domains, 3 fibronectin (Fn) III repeats in the extracellular region, and 4 conserved cytoplasmic (CC) motifs in the intracellular region (6). Myo9b contains a motor domain in the head region, 4 IQ motifs in the neck region, and a RhoGAP domain in the tail region (27) . To characterize the ROBO1 and Myo9b domains involved in ROBO1-Myo9b interaction, we used a panel of ROBO1 deletion mutants (Supplemental Figure 2B and ref. 35 ) and constructed a series of Myo9b mutants (Supplemental Figure  2D) . A co≠ IP assay was performed using lysates of H1299 cells that had been cotransfected with Flag≠ tagged Myo9b (Flag≠ Myo9b) and HA≠ tagged ROBO1 (the full≠ length or deletion mutants). All 4 CC motifs in the ICD of ROBO1 contributed to ROBO1-Myo9b interac≠ tion, whereas deletion of the ICD completely eliminated the interac≠ tion between ROBO1 and Myo9b (Supplemental Figure 2C) . On the other hand, the RhoGAP domain in Myo9b is required for Myo9b association with ROBO1 (Supplemental Figure 2E) . Therefore, Myo9b interacts with the ICD of ROBO1 via the RhoGAP domain.
was expressed in lung cancer cell lines (Supplemental Figure 1, A  and B) , in contrast to a previous report that Myo9b expression was restricted to the immune system (25) .
To confirm the interaction between ROBO1 and Myo9b in mammalian cells, we performed co≠ IP experiments using HEK293 cells transfected with plasmids encoding ROBO1 with an HA tag (HA-ROBO) or a vector control. Myo9b was detected in the immunoprecipitates formed with a specific anti≠ HA Ab from the HA-ROBOñ expressing cells, but not from the control cells (Supplemental Figure 2A) . To examine whether the endogenously expressed ROBO1 and Myo9b proteins were associated with each other in lung cancer cells, H1299 cell lysates were immunoprecip≠ itated using anti≠ Myo9b or control IgG, followed by immunoblot≠ ting with anti≠ ROBO1. ROBO1 was detected in the proteins immu≠ noprecipitated by anti≠ Myo9b Ab, but not by control IgG ( Figure  2A ). These results indicate that endogenous ROBO1 interacts with Myo9b in H1299 lung cancer cells. In addition, the GST pull≠ down experiments were performed using the GST-RBD to examine RhoA activation after H1299 cells were transfected with the control or with 2 Myo9b≠ spe≠ cific siRNAs. When Myo9b was downregulated in H1299 cells, SLIT≠ induced RhoA activation was markedly reduced ( Figure  2E and Supplemental Figure 2J ), demonstrating that Myo9b is required for SLIT≠ induced RhoA activation in H1299 cells. Together, these data show that Myo9b is indeed important for SLIT/ROBO signaling in lung cancer cells.
Myo9b inactivates RhoA through its RhoGAP domain in lung cancer cells. Since Myo9b is critical for SLIT/ROBO signaling in the regulation of RhoA activity, we next tested whether Myo9b can specifically inactivate RhoA in lung cancer cells. We exam≠ ined the effect of Myo9b on small GTPases, including RhoA, CDC42 and Rac1, in H1299 cells. Following transfection with the control or 2 Myo9b≠ specific siRNAs, H1299 cell lysates were We then asked whether Myo9b could directly interact with ROBO1. GST pull≠ down experiments were performed using the purified proteins GST≠ tagged Myo9b RhoGAP domain (GST≠ GAP) and maltose≠ binding proteinñ His6ñ tagged ROBO-ICD domain (MBP-His 6 ≠ ROBOICD) (see Supplemental Figure 2F for individual purified proteins). Following GST pull≠ down, the GST-GAP protein associated with MBP-His 6 ≠ ROBOICD was detected by Western blotting using anti≠ His Ab ( Figure  2B ), demonstrating that the purified Myo9b RhoGAP domain directly interacted with the ROBO-ICD domain. Consis≠ tently, the yeast 2≠ hybrid assay detected interaction between the ROBO-ICD and Myo9b (either GTPase≠ activating protein [GAP] alone or the protein kinase C conserved region 1 [C1] and RhoGAP domain [C1-GAP]) (Supplemental Figure 2G) . These experiments indicate that the Myo9b RhoGAP domain can directly interact with the ICD of ROBO1.
Because Myo9b interacts with ROBO1 and displays RhoA≠ specific RhoGAP activity, we next tested whether Myo9b plays a role in mediating SLIT/ROBO signaling in the suppres≠ sion of cell migration and the activation of RhoA in lung cancer cells. The wound≠ healing experiments were performed follow≠ ing knockdown of Myo9b expression using 2 independent Myo≠ 9b≠ specific siRNAs (siMyo9b) in H1299 cells. Immunoblotting experiments confirmed that siMyo9b efficiently reduced Myo9b RhoGAP domain and RhoA. GST pull-down experiments were performed using recombinant WT or mutant forms of the GST-Myo9b RhoGAP domain and the cell lysates from HEK293 cells transfected with a Myc-RhoA plasmid. jci.org prepared and incubated with GST-RBD or GST-PBD, respec≠ tively. The specific GTPase activity was determined by immu≠ noblotting with corresponding Abs following the GST pull≠ down experiment. When Myo9b was downregulated, the levels of active RhoA and GTP-RhoA were dramatically increased, whereas the levels of either active CDC42 or active Rac1 were not affected (Supplemental Figure 4A) . These data support the idea that Myo9b specifically inactivates RhoA in lung cancer cells. To examine whether the GAP activity of Myo9b depends on its RhoGAP domain, we performed a GST pull≠ down exper≠ iment using H1299 cells following transfection with plasmids expressing either the WT or deletion mutant Myo9b as Flag≠ tagged proteins, or the vector control. As expected, full≠ length Myo9b, C1-GAP, or the RhoGAP domain of Myo9b reduced active RhoA levels, but not those of CDC42 or Rac1 (Supple≠ mental Figure 4B ). To further examine the effects of the Myo9b RhoGAP domain on small GTPase activity, we prepared highly purified Myo9b RhoGAP domain protein for the GST pull≠ down experiments. Extracts from HEK293T cells respectively trans≠ fected with Myc≠ RhoA, Myc≠ CDC42, or Myc≠ Rac1 were incu≠ bated with the purified RhoGAP domain at different concen≠ trations. Then, we performed GST pull≠ down experiments with active levels of small GTPases detected by Western blotting.
Consistent with our present findings and with those of previous studies of Myo9b, the purified Myo9b RhoGAP domain protein inhibited RhoA in a dose≠ dependent manner without affecting CDC42 or Rac1 (Supplemental Figure 4C) , indicating that the Myo9b RhoGAP domain specifically modulates RhoA activity.
Structural analyses of the RhoGAP domain in Myo9b.
To exam≠ ine the mechanism underlying the RhoA≠ specific RhoGAP activity of Myo9b, we crystallized the Myo9b RhoGAP domain and deter≠ mined its structure at 2.2-≈ resolution (Figure 3 and Supplemental Table 4 ). From the overall structure, the Myo9b RhoGAP domain adopts a canonical RhoGAP fold with 9 α helices (namely, αA0 to αG, according to the canonical RhoGAP domain structure) (Fig≠ ure 3, B-D). Among these helices, αA, αB, αE, and αF are arranged as a 4≠ helix bundle, forming the core of the structure (Figure 3 , C and D). This 4≠ helix bundle is capped by the shortest αA0 helix that is likely to complete the core structure. One side of the central 4≠ helix bundle (the αA/αB side) immediately packs with αA1 (Fig≠ ure 3, C and D), whereas at its opposite side (the αE/αF side), αC and αD form a helical hairpin that protrudes from the 4≠ helix bun≠ dle core. Interestingly, the last helix, αG, exhibits an orientation perpendicular to the other helices (except for αA0) and crosses the deep cave formed between the αC/αD helical hairpin and the cen≠ tral 4≠ helix bundle (Figure 3, C and D) . The overall structure of the Myo9b RhoGAP domain is sim≠ ilar to that of the canonical RhoGAP domain of p50RhoGAP, especially in the central 4≠ helix bundle (Supplemental Figure 5) . Consistent with this feature, the structure≠ based sequence align≠ ment showed that the residues responsible for the 4≠ helix bundle formation are highly conserved among different members of the RhoGAP family (Supplemental Figure 5A) . In contrast to the cen≠ tral 4≠ helix bundle, the neighboring αA1, αG, and αC/αD helical hairpin showed some differences between the Myo9b RhoGAP and p50RhoGAP domains; e.g., the loop between αA1 and αB of the Myo9b RhoGAP domain is shorter than that of p50RhoGAP, whereas the last helix αG is relatively longer (Supplemental Figure  5 , B-E). These structural differences may distinguish the Myo9b RhoGAP domain from RhoGAP domains in other proteins.
The Myo9b RhoGAP domain contains a unique patch that spe≠ cifically recognizes RhoA. On the basis of the structure of the p50RhoGAP/RhoA complex (Supplemental Figure 6) , the RhoA≠ binding site within the RhoGAP domain is formed by αA1, αB, αF, αG, and the αA/αA1 and αF/αG loops and can be divided into 3 patches (patches I, II, and III) with the active arginine finger located in the αA/αA1 loop. Consistent with its structural similarity to the p50RhoGAP domain (Supplemental Figure 6) , the Myo9b RhoGAP domain contains a similar site with 3 patches that potentially form a binding surface to interact with RhoA (Figure 3 , E-G). More specifi≠ cally, patch I consists of R1735 from the αA1/αB loop and K1772 and R1776 from αB ( Figure 3 , B and F); patch II is composed of A1739, N1741, R1742, and R1744 from the N≠ terminal half of αA1 (Figure  3 , B and G); and patch III is formed by I1848 and P1852 from αF and V1870 from αG ( Figure 3, B and F) . Given that these patches formed a potential binding site ( Figure 3E and Supplemental Figure  6 ), we confirmed by GST pull≠ down assay that the Myo9b RhoGAP domain indeed directly interacted with RhoA ( Figure 4E) .
The above≠ described similarity between the Myo9b RhoGAP and p50RhoGAP domains prompted us to build a structural model of the Myo9b RhoGAP/RhoA complex by replacing the RhoGAP domain in the p50RhoGAP RhoGAP/RhoA complex structure with the Myo9b RhoGAP domain. This model was further refined by molecular dynamics simulation in solution. As expected, the final structural model of the Myo9b RhoGAP/ RhoA complex resembled that of the p50RhoGAP RhoGAP/ RhoA complex, adopting a similar mode of interaction with 3 patches binding to RhoA (Figure 4 , A and B, and Supplemental Figure 7) . Consistent with these structure≠ based analyses, point mutations in patch II of the Myo9b RhoGAP domain to reverse its charged property, including A1739E, N1741E, and R1742E muta≠ tions, each remarkably decreased binding of the Myo9b RhoGAP domain to RhoA, thereby impairing the subsequent inactivation of RhoA (Figure 4, D and E) . In contrast, the A1739V mutation did not affect Myo9b RhoGAP-RhoA interaction, whereas the A1739N mutation did (Figure 4 , D and E), again, supporting an essential role of a hydrophobic interaction between A1739 of Myo9bGAP and the A3 helix of RhoA. Taken together, the Myo9b RhoGAP domain contains a unique positively charged patch II that specifi≠ cally recognizes and inactivates RhoA.
Additionally, we substituted the corresponding amino acid residues in the A3 helix of CDC42 or Rac1 with those of RhoA for binding to patch II of RhoGAP, generating mutant forms of CDC42S88D/K94P or Rac1A88D/R94P/A95E. In a GST pull≠ down experiment, we demonstrated that the Myo9b RhoGAP domain inactivated these mutant forms of CDC42 and Rac1, but not the WT forms of CDC42 or Rac1 (Supplemental Figure 8, A  and B) . Consistent with this, the binding of Myo9b RhoGAP to Figure 6 ). Specifically, the positively charged patch I interacts with the negatively charged switch II, patch II packs with the A3 helix, and patch III forms extensive hydrophobic contacts with switch I. Because patches I and III of the RhoGAP domain are highly conserved, but patch II is diverse in different RhoGAP family proteins (Supplemental Figure 5A and Supplemental Figure 6 ), the specificity of the Myo9b RhoGAP domain toward RhoA may likely be determined by its patch II. Consistent with this feature, the structure≠ based sequence alignment of different Rho family proteins (RhoA, CDC42, and Rac1) shows that switch I and switch II, which are responsible for interacting with patch III and patch I of the RhoGAP domain, are also highly conserved (Supplemental Figure 7) , whereas the sequences for the A3 helix, the corresponding site for binding to patch II, are diverse.
To further understand the specific recognition of RhoA by the Myo9b RhoGAP domain, we analyzed the interaction inter≠ face between patch II and the A3 helix. Patch II of the Myo9b RhoGAP domain is enriched in positively charged residues (R1742 and R1744) that form electrostatic interactions with negatively charged residues (D90 and E97) in the A3 helix of RhoA ( Figure  4C ). Moreover, N1741 in patch II is likely to interact with E93 in the A3 helix, and A1739 in patch II also forms hydrophobic inter≠ actions with the A3 helix ( Figure 4C ). In contrast, D90 is replaced by S88 in CDC42, and D90 and E97 are substituted with A88 and We further tested whether SLIT2 inhibits Myo9b RhoGAP activity through the ROBO1 receptor. We coexpressed a ROBO1 mutant lacking its ICD as a GFP≠ tagged protein (GFP-DN-ROBO) and Flag≠ tagged Myo9b≠ GAP in H1299 cells. In these cells, SLIT2 treatment failed to induce RhoA activation, demonstrating that the inhibitory effect of SLIT2 on Myo9b≠ GAP activity is ROBO1 dependent ( Figure 5F ).
SLIT2 suppresses lung cancer invasion and metastasis. The data presented above allow us to define a SLIT/ROBO/Myo9b/RhoA signaling pathway that inhibits lung cancer cell migration in vitro. These data also suggest that SLIT2 is a suppressor for lung can≠ cer. To investigate the role of SLIT2 in patients with lung cancer, we collected 25 pairs of lung tumor samples with the adjacent nontumor tissues. The expression of SLIT2 mRNA was analyzed by real≠ time RT-PCR with GAPDH as an internal control. SLIT2 expression was significantly decreased in lung tumors as compared with expression levels detected in the paired adjacent control tis≠ sues ( Figure 6A ). To survey data on more patients, we analyzed published datasets for SLIT2 expression in lung cancer using the Oncomine database (www.oncomine.org) and gene microarray data analysis tools (36) . Data from multiple datasets show that SLIT2 gene expression is significantly downregulated in human lung cancer samples as compared with controls (Supplemental Fig≠ ure 9A), consistent with the findings of a previous report involving a relatively small cohort (20) . Kaplan≠ Meier analyses of different human lung cancer microarray datasets, including those found in the caArray database (www.kmplot.com) and in the NCBIí s Gene Expression Omnibus (GEO) database (GEO GSE31210) (37), show that higher levels of SLIT2 expression are associated with longer overall survival (OS) and progression≠ free survival (PFS) of patients (Supplemental Figure 9, B and D) . Even among late≠ stage lung can≠ cer patients with grade III tumors, lower SLIT2 expression levels were associated with a shorter OS time (Supplemental Figure 9C) . Importantly, in lung cancer patients with lymph node metastasis, higher SLIT2 expression levels still correlated with a better prog≠ nosis of OS (Supplemental Figure 9C) . Our analysis of 178 lung cancer samples from The Cancer Genome Atlas (TCGA) published dataset (38) demonstrates that approximately 8%, 7%, and 7% of mutant forms of CDC42 or Rac1 dramatically increased as com≠ pared with the that seen in the WT form (Supplemental Figure  8, C and D) , supporting the notion that the specific electrostatic interaction between patch II and the A3 helix may determine the specific recognition of RhoA by the Myo9b RhoGAP domain.
SLIT/ROBO signaling inactivates the Myo9b RhoGAP domain. Detection of the interaction between the ICD of ROBO1 and the Myo9b RhoGAP domain prompted us to investigate whether ROBO1 affected Myo9b RhoGAP domain activity. We performed a GST pull≠ down assay using GST-RBD and HEK293T cell lysates transfected with Myc≠ RhoA in the presence of various combina≠ tions of purified proteins: Myo9b RhoGAP and ROBO-ICD (as an MBP≠ tagged protein). The effect of ROBO-ICD on Myo9b RhoGAP activity was determined by Western blotting analysis of the pull≠ down products. Interestingly, Myo9b inhibitory effects on RhoA were suppressed by the addition of ROBO-ICD in a dose≠ dependent manner ( Figure 5A, lanes 3-5) , whereas addition of a control MBP≠ tagged protein alone showed no effect ( Figure  5A, lane 2) . Similarly, GST pull≠ down experiments using H1299 lung cancer cells that coexpressed a Flag≠ tagged Myo9b RhoGAP protein, together with different levels of full≠ length HA≠ tagged ROBO1 (HA-ROBO), demonstrated that ROBO1 suppressed Myo9b RhoGAP activity in RhoA inactivation ( Figure 5B ). Taken together, these results indicate that the ICD of ROBO suppresses Myo9b RhoGAP activity and prevents the conversion of GTP≠ RhoA to GDP-RhoA.
We next tested whether ROBO-ICD interfered with RhoGAP≠ RhoA interaction by performing GST pull≠ down experiments using purified ROBO-ICD protein and HEK293T cell lysates transfected with plasmids encoding Myc≠ tagged RhoA. These experiments showed that ROBO-ICD protein blocked the interac≠ tion of RhoGAP with RhoA in a concentration≠ dependent manner ( Figure 5C ), providing one mechanistic explanation for the inhibi≠ tion of Myo9b RhoGAP activity by ROBO-ICD.
To further characterize the effect of SLIT2 on Myo9b RhoGAP activity in lung cancer cells, we performed GST-RBD pull≠ down experiments on a stable H1299 cell line that overexpressed SLIT2 
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We further analyzed the lung cancer samples to determine whether there was a correlation between Myo9b expression and the clinicopathological features of lung cancer patients. We found no significant correlation between Myo9b expression and patientsí age, sex, or tumor size. However, the majority of patients who had lymph node metastasis showed increased Myo9b expression (15 of 16 patients, Supplemental Table 3 ). Thus, Myo9b expres≠ sion was correlated with lymph node metastasis, suggesting that Myo9b may promote lung cancer metastasis. In addition, 35 of 43 lung cancer patients with high Myo9b expression levels had an advanced pathological disease stage (Supplemental Table 3 ). Consistently, we found that MYO9B mRNA levels were higher in the more advanced≠ stage lung tumors ( Figure 7D) . Therefore, increased Myo9b expression is associated with lung cancer pro≠ gression in patients.
We also examined the correlation between OS of patients and their Myo9b expression levels using the Kaplan≠ Meier method. Higher Myo9b expression levels were associated with a lower probability of OS ( Figure 7E ). Our analyses of the published lung cancer datasets (37) consistently showed that patients with higher levels of Myo9b expression had significantly shorter PFS than did those expressing lower levels of Myo9b ( Figure 7F ). These results support the notion that Myo9b functions as a tumor≠ promoting factor in lung cancer progression.
Discussion
Lung cancer is a leading cause of death and a major health prob≠ lem in both developed and developing countries (39). Significant efforts have been made to understand the pathogenetic mecha≠ nisms underlying lung tumorigenesis (refs. 2-4, and references within). A number of tumor≠ promoting mutations have been found in EGFR and KRAS genes in patients with lung cancer. Lung cancer tumorñ suppressor genes, including TP53, P16, LKB1/STK11, NF1, RASSF1, APC, BRG1, PTEN, and RB, which regulate cell cycle, cell proliferation, and cell death, have also been discovered (reviewed in refs. 40, 41). However, little is known about the endogenous mechanisms that suppress lung cancer invasion and metastasis.
In this study, we present both in vitro and in vivo evidence that supports an important role of SLIT2 in the suppression of lung can≠ cer. We show that SLIT2 inhibited migration of lung cancer cells in a ROBO≠ dependent manner. This is consistent with our previous studies of breast cancer (32) and with other studies of cancers such as glioma (42) and medulloblastoma (43) . In the xenograft mouse model used in the present study, we demonstrate that increased expression of SLIT2 reduced tumor formation, local invasion, and lung metastasis.
The expression of SLIT1 is restricted to the brain, whereas both SLIT2 and SLIT3 are highly expressed in brain and lung tissues (13, 44) . Consistent with previous studies (18, 20) , our analyses show that SLIT2 is substantially downregulated in human lung cancer and that low SLIT2 expression levels are associated with poor survival of lung cancer patients. It has been reported that in developing or post≠ natal mouse lung tissues, SLIT2 is expressed in the mesenchymal compartment and larger airway epithelium, whereas SLIT3 expres≠ sion is detected in the endothelium of large vessels associated with conducting airways (44) . It is possible that the human SLIT2/3 genes expressed in lung tissue play a role in restricting lung cancer the human lung cancer cases showed genetic alterations (includ≠ ing homozygous deletion and mutations) in the SLIT2, SLIT3, or ROBO1 genes, respectively (Supplemental Figure 9 , E-G), suggest≠ ing that the SLIT or ROBO1 gene plays an important role in lung cancer pathogenesis. Taken together, these data strongly support a role of SLIT2 in suppressing lung cancer in humans.
To determine whether SLIT2 could suppress lung cancer inva≠ sion and metastasis in vivo, we established a xenograft animal model using H1299 cells in which endogenous SLIT2 expression levels were low. We prepared stable H1299 cell lines expressing human SLIT2 (H1299SLIT) or the vector control (H1299Ctr) and examined their behavior in the animal model. We monitored tumor formation following s.c. injection of either H1299Ctr or H1299SLIT cells into nude mice. By day 24 after tumor cell injec≠ tion, palpable tumors were detected. Animals were euthanized and examined for local tumor invasion and lung metastasis. In the H1299Ctr group, all 10 mice injected developed s.c. tumors, whereas in the H1299SLIT group, only 7 of 10 mice showed detect≠ able s.c. tumors ( Figure 6E ). The average volume and weight of the primary tumors in the H1299Ctr group were significantly greater than those of the SLIT2≠ expressing tumors in the H1299SLIT group ( Figure 6 , B-D), demonstrating that SLIT2 expression in H1299 cells suppresses tumor growth or invasion in vivo. Histo≠ logical examination of these primary tumors revealed that the majority of H1299Ctr tumors exhibited local invasion, with irregu≠ lar borders and numerous microcapillaries adjacent to invading tumor cells, whereas most tumors derived from H1299SLIT cells were surrounded by fibrous capsules with smooth, clear borders (Figure 6 , F and G, and Supplemental Table 1 ). These findings indicate that SLIT2 expression significantly reduced invasion by H1299 lung cancer cells in vivo. We performed further histologi≠ cal examination of mouse lung tissues to evaluate lung metastasis. In the H1299Ctr group, all mice showed lung metastasis, whereas only 3 of 10 mice in the H1299SLIT group showed lung metastasis ( Figure 6H and Supplemental Table 2 ). In these mice, H1299SLIT cells induced much reduced lung metastasis as compared with the H1299Ctr cells, in terms of both the size and number of lung metastatic tumors ( Figure 6 , H and I, and Supplemental Table 2 ). These results demonstrate that SLIT2 inhibits lung cancer inva≠ sion and metastasis in our mouse model, supporting the idea that SLIT2 is a lung cancerñ suppressor gene.
Myo9b is highly expressed in lung cancer, and high Myo9b expres≠ sion levels are correlated with lung cancer progression. We investi≠ gated the potential involvement of Myo9b in human lung cancer. First, we examined Myo9b expression in a tissue≠ array panel containing 60 human lung cancer samples with corresponding matched adjacent nontumor tissues. Fifty≠ six of the sixty (93%) lung cancer tissue samples showed positive Myo9b immunostain≠ ing signals, whereas only 14 of 60 (23%) paratumor control tis≠ sue samples were Myo9b positive ( Figure 7A for a representative tissue pair and Figure 7B) . Consistent with our immunostaining data, real≠ time RT-PCR analyses of a separate cohort of 25 pairs of human lung cancer and control samples showed that MYO9B mRNA levels were significantly increased in the lung cancer sam≠ ples as compared with the levels detected in the adjacent nontu≠ mor tissue controls ( Figure 7C) , further supporting the finding that Myo9b expression is upregulated in human lung cancer.
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in lung cancer cells, indicating that activated RhoA suppresses lung cancer cell migration (Supplemental Figure 1, F and G) . In our study, increased SLIT2 expression or SLIT2 treatment led to RhoA activation in lung cancer cells. Lung cancer cells expressing SLIT2 showed significantly reduced cell migration in vitro and decreased cancer invasion and metastasis in vivo. These findings led us to propose that SLIT2 activates RhoA signaling to inhibit lung cancer cell migration. A recent study shows that miR-194 suppresses nonñ small≠ cell lung cancer metastasis through activation of the RhoA pathway, producing enhanced development of actin stress fibers and impaired migration of cancer cells (50) . Ablation of p120≠ cat≠ enin enhances invasion and metastasis of human lung cancer cells by inactivating RhoA (51), consistent with our results. Recent studies suggest that RhoA activity may have a tumor≠ suppressive role in diffuse gastric cancer and T cell lymphoma (52) (53) (54) (55) (56) (57) (58) .
Our findings led us to propose a working model for the newly defined SLIT/ROBO/Myo9b/RhoA pathway in mediating the inhibitory effect of SLIT2 on lung cancer cell migration (Figure 8 ). In this model, SLIT2 acts to suppress lung cancer cell migration in a ROBO≠ dependent manner. The ICD of ROBO1 binds to the RhoGAP domain of Myo9b, resulting in the suppression of Myo9b RhoGAP activity and leading to increased levels of GTP-RhoA. These data, to our knowledge, uncover a previously unknown role of Myo9b in lung cancer.
It should be noted that studies from several groups, including our own, have shown that SLIT/ROBO signaling in neurons and in different types of cancers may use distinct signal transduction pathways. For example, the SLIT/ROBO/srGAP/CDC42 pathway seems to play a major role in neurons (e.g, see ref. 33), whereas USP33 is required for SLIT/ROBO signaling in commissural neu≠ rons and breast cancer cells (e.g., refs. 32, 35). Here, our data demonstrate an important role for the SLIT/ROBO/Myo9b/RhoA pathway in lung cancer. The observation that Myo9b expression is increased in multiple cohorts of lung cancer samples also suggests that Myo9b is a potential therapeutic target for lung cancer. It is conceivable that reducing or silencing Myo9b expression or block≠ ing its activity in lung cancer cells may provide therapeutic bene≠ fits for patients with metastatic lung cancer who show increased Myo9b expression levels. Our study defines what is, to our knowl≠ edge, a previously unrecognized signal transduction pathway for SLIT in the suppression of lung cancer invasion and metastasis that involves ROBO/Myo9b/RhoA signaling. Future studies are necessary to understand the cross≠ communication of the SLIT/ ROBO/Myo9b/RhoA pathway with other signal transduction pathways critical for the extremely complex process of lung cancer development and progression.
Methods
Crystallization, data collection, and structure determination. Crystalli≠ zation of the Myo9b RhoGAP domain (15 mg/ml in 50 mM Tris≠ HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT) was achieved at 16∞ C using the vapor diffusion method (sitting drop) in 0.2 M NH 4 Ac, 0.1 M Bis≠ Tris, pH 6.0, and 20% PEG 3350. Before being flash≠ fro≠ zen in liquid nitrogen, the crystal was cryoprotected with the mother liquor supplemented with 1 M LiAc. Diffraction data were collected at the beamline BL17U of the Shanghai Synchrotron Radiation Facil≠ ity with a wavelength of 0.979 ≈ at 100 K. The dataset was processed invasion and metastasis. Interestingly, approximately 8% or 7% of patients with lung cancer showed genetic alterations in the SLIT2 or SLIT3 genes, respectively. In addition, mutations in the human ROBO1 gene have been detected in approximately 7% of lung can≠ cer cases (Supplemental Figure 9) . Together, our results strongly support a role of SLIT/ROBO signaling in the suppression of lung cancer invasion and metastasis.
Myo9b is a RhoGAP protein that modulates lamellipodia protrusion and tail retraction by suppressing RhoA activation in migrating immune cells (25) . To our knowledge, the involvement of Myo9b in cancer has not been reported previously. The data presented here indicate that Myo9b is a ROBO≠ interacting protein that is highly expressed in human lung cancer. The ICD of ROBO1 interacts with the Myo9b RhoGAP domain and suppresses Myo9b RhoGAP activity, as illustrated in our working model depicted in Figure 8 . Thus, SLIT2/ROBO1 signaling suppresses Myo9b RhoGAP activity in the conversion of GTP-RhoA to GDP-RhoA, leading to increased GTP-RhoA. Our analyses of samples from patients show that increased expression of Myo9b correlates with advanced disease stage, lymph node metastasis, poor OS, and shortened PFS. Taken together, our study uncovers what is, to our knowledge, a previously unknown pathway, SLIT/ROBO/Myo9b/ RhoA, that mediates SLIT/ROBO signaling in lung cancer cells.
Myo9b contains a RhoGAP domain at its carboxyl terminus (see Figure 3A) that has been reported to inactivate RhoA, but not CDC42 or Rac1 (45) . However, the molecular mechanism under≠ lying the specific GAP activity of this RhoGAP domain toward RhoA remained unclear. In this study, we have determined the structure of the Myo9b RhoGAP domain (Figure 3 ). In comparison with other RhoGAP domains, the Myo9b RhoGAP domain con≠ tains a unique positively charged patch II that can specifically rec≠ ognize the negatively charged A3 helix of RhoA (Figure 4 and Sup≠ plemental Figure 5 ). Mutations in this patch II region decreased the binding of the Myo9b RhoGAP domain to RhoA and impaired the subsequent RhoA inactivation (Figure 4) . Moreover, the cor≠ responding interaction site in CDC42 or Rac1 for patch II is dif≠ ferent from that in RhoA and would not be well recognized by the Myo9b RhoGAP domain (Supplemental Figure 7) . Consistent with previous data (46), the specificity of the RhoGAP domain for Rho GTPases is most likely determined by the interaction between patch II and the A3 helix. Together, our data reveal a structural basis for the RhoA≠ specific GAP activity of the Myo9b RhoGAP domain. It is likely that the paradigm in which the unique posi≠ tively charged patch II identified in the Myo9b RhoGAP domain specifically recognizes RhoA may also be extended to other pro≠ teins containing such RhoA≠ specific RhoGAP domains.
The Rho family of GTPases plays important roles in cell migration by modulating actin and microtubule dynamics, myo≠ sin activity, and cellñ extracellular matrix and cell≠ cell interac≠ tions (30, 31, 47) . The roles of RhoA in cancer cell invasion and migration are highly complex. RhoA is capable of mediating stress fiber formation and generating the contractile force needed for retraction of the trailing edge during cell migration (refs. 47, 48, and references within). RhoA was also reported to function in membrane ruffling and lamellae formation (49) . However, the expression and function of RhoA in lung cancer remain unclear. Our data show that constitutively active RhoA inhibits migration
Immunohistochemical analysis of human lung cancer tissues. IHC was performed on formalin≠ fixed, paraffin≠ embedded human lung cancer tis≠ sue sections. Polyclonal anti≠ Myo9b Ab (1:350) was used with HRP≠ con≠ jugated goat anti≠ rabbit secondary Ab and DAB for color development. For a control, the samples were incubated with the preimmune rabbit IgG instead of the primary Ab. Myo9b immunostaining was scored from 0-3 according to the signal intensity and distribution (0, <5%; 1, 5%ñ 25%; 2, 25%ñ 50%, and 3, >50%). Cytoplasmic yellow granuleñ like staining of tumor cells and staining that accounted for more than 50% in the tissue sections were considered strong Myo9b staining and given a score of 3. Tissues with a score of 1 or lower were considered to have low Myo9b expression, whereas scores or 2 or higher were considered to have high Myo9b expression.
Microarray data analysis. The Oncomine database and gene microarray analysis tool (36), a repository for published cDNA microarray data, was explored for SLIT2 mRNA expression in lung cancer and control samples. Oncomine algorithms were used to con≠ duct statistical analyses of the differences in SLIT2 expression. For patient survival analyses, the association between SLIT2 or MYO9B expression and OS or PFS was assessed by Kaplan≠ Meier plotting, followed by log≠ rank testing for significance (37) . cBioPortal software (www.cbioportal.org) was used to analyze gene mutation and gene expression correlations in 178 human lung cancer tissue samples (38) .
Statistics. Comparisons were made using a 2≠ tailed Studentí s t test, a Mann≠ Whitney U test, or 1≠ way ANOVA. Pearsoní s χ 2 test was used to evaluate the relationship between Myo9b expression and clinicopathological features. Survival curves were calculated by the Kaplan≠ Meier method, and comparison was made using the log≠ rank test. A P value of less than 0.05 was considered statistically significant. All statistical calculations were performed using GraphPad Prism 5 (GraphPad Software) or SPSS 13.0 (IBM) software.
Study approval. All animal experiments were conducted accord≠ ing to institutional and national guidelines and following protocols approved by the IACUCs of the University of Chinese Academy of Sci≠ ences, the Chinese Academy of Sciences, and Northwestern Univer≠ sity. All specimens were obtained with written informed consent of the patients in accordance with approved protocols and institutional and national guidelines.
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JYW conceived the project idea, designed the studies, and super≠ vised all aspects of the project. RK designed and carried out exper≠ iments and analyzed data. FY carried out experiments related to Myo9bGAP domain structural analyses. WF and LZ designed and supervised the structural analyses. JYW, XC, JL, LZ, and JR con≠ tributed to experiments and project coordination. PW, XL, YS, YN, KW, DF, and RK contributed to tissue sample collection and analy≠ ses. RK, FY, WF, LZ, and JYW wrote the manuscript. and scaled using iMOSFLM (59) and the SCALA module in the Computational Collaborative Program No. 4 (CCP4) software suite (60) . The structure of the Myo9b RhoGAP domain was solved by the molecular replacement method using the p50RhoGAP RhoGAP domain (Protein Data Bank [PDB] code 1OW3) as a research model with PHASER (61). The structure model was further manually built with COOT (62) and refined with Phenix software (63) . The overall quality of the final structural model of the Myo9b RhoGAP domain was assessed by PROCHECK (64) . The protein structure figures were prepared using the PyMOL program (http://www.pymol.org). The statistics for the data collection and structural refinement are summarized in Supplemental Table 4 . The coordinate of the crystal structure of the Myo9b RhoGAP domain is deposited in the PDB (accession number 5C5S).
Molecular dynamics simulations. The initial structural model of the Myo9b RhoGAP/RhoA complex was obtained by replacing the RhoGAP domain in the p50RhoGAP RhoGAP/RhoA complex struc≠ ture (PDB code 1OW3) with the Myo9b RhoGAP domain. The model structure was then soaked in a 96 × 96 × 96 ≈ 3 water box, which included 26 Mg 2+ and 48 Cl ñ to neutralize the system. The NAMD package (65) and the CHARMM22 all≠ atom force field (66) were used for energy minimization and molecular dynamics simulations. Under periodic boundary conditions, a 12-≈ cutoff was used for van der Waals interactions, and particle mesh Ewald summation was used to calcu≠ late the electrostatic interactions. Four independent simulations were performed. For each simulation, energy was first minimized in multi≠ ple steps to avoid any possible clashes. The energy≠ minimized system was then equilibrated for 10 ns, with the temperature controlled at 310 K by Langevin dynamics and the pressure controlled at 1 atm by the Langevin piston method. With the equilibrated structures, 50≠ ns free dynamics simulation was performed for each system. The simu≠ lation trajectories were analyzed with the Visual Molecular Dynamics (VMD) program (67) .
Animal experiments. H1299Ctr and H1299SLIT cells were inocu≠ lated s.c. into the right flank (6 × 10 6 cells/mouse; n = 10) of 6≠ week≠ old female BALB/c nude mice as described previously (68) . Tumor volumes (V) were measured every week and calculated using the equa≠ tion V(mm 3 ) = a × b 2 /2, in which a was the largest dimension and b was the perpendicular diameter. Animals were euthanized when the larg≠ est primary tumor grew to approximately 1,000 mm 3 or the animalí s condition deteriorated. Lung tumors and surrounding normal lung tissue were removed and dissected for histological examination. Tis≠ sues were fixed in 4% paraformaldehyde and embedded in paraffin. H!E staining and immunohistochemical analyses were performed on tissue sections as previously reported (42) .
Tissue microarray and immunohistochemical staining. Deidentified lung tumor tissue samples were collected from 60 consented patients at Xijing Hospital (Xií an, China) following institutional and national guidelines. The study cohort consisted of tumors and correspond≠ ing adjacent nontumor lung tissues from these same patients. Array blocks were sectioned to produce serial 4≠ μm sections for immunohis≠ tochemical staining. Tissue microarray sections were immunostained with the Myo9b Ab, the specificity of which was confirmed by antigen competition experiments (Supplemental Figure 10 and Supplemental Methods). Myo9b immunostaining signals are mostly in the cytoplasm of lung cancer cells that are positive for E≠ cadherin but not the mes≠ enchymal cells (see Supplemental Figure 11 ).
